News headlines about Amedica (NASDAQ:AMDA) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amedica earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.1539795821639 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Amedica traded down $0.02, hitting $1.09, during trading hours on Thursday, Marketbeat.com reports. 112,334 shares of the stock traded hands, compared to its average volume of 635,225. Amedica has a one year low of $1.02 and a one year high of $6.96.
Several analysts recently issued reports on AMDA shares. Maxim Group reissued a “hold” rating on shares of Amedica in a research note on Tuesday, March 6th. ValuEngine raised Amedica from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Amedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.